Ovarian Cancer Coverage from Every Angle

ESMO 2019: PARP Inhibitor of Benefit in Newly Diagnosed Advanced Ovarian Cancer

By: Hillary Ojeda
Posted: Friday, October 11, 2019

According to the phase III PRIMA/ENGOT-OV26/GOG-3012 trial, treatment with the PARP inhibitor niraparib led to improved progression-free survival compared with placebo in patients with newly diagnosed advanced disease who were treated with this agent after achieving a response to first-line platinum-based chemotherapy. Antonio González Martin, MD, PhD, of the Universidad de Navarra, Spain, and colleagues, who presented these findings at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona (Abstract LBA1), suggested niraparib should be considered a treatment option for patients with advanced ovarian cancer after chemotherapy.

“Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received niraparib had significantly longer progression-free survival than those who received placebo, regardless of the presence or absence of homologous-recombination deficiency,” the investigators concluded.

A total of 733 patients were enrolled in the double-blind, placebo-controlled study and were randomly assigned to treatment with niraparib (n = 487) or placebo (n = 246). Of the study patients, 373 had homologous recombination–deficiency (HRD; niraparib, 247; placebo, 126). The patients were either newly diagnosed with advanced high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer with a complete or partial response to first-line platinum-based chemotherapy. They received either 300 mg of oral niraparib or placebo once daily.

Compared with patients in the placebo group, patients who received niraparib had better progression-free survival (13.8 vs 8.2 months) for the entire population. As for the HRD-positive subgroup, the median progression-free survival with niraparib was 21.9 months, compared with 10.4 months with placebo. There were no treatmen- related deaths, and the most common grade ≥ 3 adverse event was anemia (31%).

Disclosure: The study authors’ disclosure information can be found at cslide.ctimeetingtech.com.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.